Medicine Capital is a boutique research fund focusing on special situations in the biotechnology space, namely the value inflection points that occur around clinical trial readouts. The Fund intends to minimize macro exposure through high turnover of binary events rather than maintaining large directional risk to the broader market and behavioral flows of capital. Companies are reviewed as standalone investments and the Fund is agnostic to long/short directionality. The Fund seeks to invest opportunistically in 50-60 scientific events per year. Email: investors@medcap.com